The benefit of lamivudine (LAM) in hepatitis B virus (HBV) infection is compromised by the progressively increasing emergence of drug-resistant mutant strains. Although the addition of adefovir dipivoxil (ADV) usually induces complete suppression of viral replication, primary non-response to ADV in LAM resistant patients has been reported in a variable percentage of cases. Here we report a case of a patient with HBV infection and hepatocellular carcinoma who started LAM therapy and subsequently developed virological breakthrough. The patient was given ADV, but HBV-DNA negativisation was not reached. However, HBV clearance was obtained when the patient was switched from ADV to tenofovir. Virological evaluations showed two well-known LAM-related mutations (rtL180M and rtM204I) in addition to reverse-transcriptase rtQ215H. This is the first case suggesting that this mutation may have an impact on viral replication. Finally, we also report that rtQ215H is responsive to tenofovir.

Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report / Micco, L; Fiorino, S; Loggi, E; Lorenzini, S; Vitale, G; Cursaro, C; Riili, A; Bernardi, M; Andreone, P.. - In: BMJ CASE REPORT. - ISSN 1757-790X. - 2009:(2009), pp. ---. [10.1136/bcr.06.2008.0287]

Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report

Bernardi M;Andreone P.
2009

Abstract

The benefit of lamivudine (LAM) in hepatitis B virus (HBV) infection is compromised by the progressively increasing emergence of drug-resistant mutant strains. Although the addition of adefovir dipivoxil (ADV) usually induces complete suppression of viral replication, primary non-response to ADV in LAM resistant patients has been reported in a variable percentage of cases. Here we report a case of a patient with HBV infection and hepatocellular carcinoma who started LAM therapy and subsequently developed virological breakthrough. The patient was given ADV, but HBV-DNA negativisation was not reached. However, HBV clearance was obtained when the patient was switched from ADV to tenofovir. Virological evaluations showed two well-known LAM-related mutations (rtL180M and rtM204I) in addition to reverse-transcriptase rtQ215H. This is the first case suggesting that this mutation may have an impact on viral replication. Finally, we also report that rtQ215H is responsive to tenofovir.
2009
2009
-
-
Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report / Micco, L; Fiorino, S; Loggi, E; Lorenzini, S; Vitale, G; Cursaro, C; Riili, A; Bernardi, M; Andreone, P.. - In: BMJ CASE REPORT. - ISSN 1757-790X. - 2009:(2009), pp. ---. [10.1136/bcr.06.2008.0287]
Micco, L; Fiorino, S; Loggi, E; Lorenzini, S; Vitale, G; Cursaro, C; Riili, A; Bernardi, M; Andreone, P.
File in questo prodotto:
File Dimensione Formato  
BMJ Case Rep.pdf

Accesso riservato

Dimensione 56.84 kB
Formato Adobe PDF
56.84 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237173
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact